Cargando…

Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism

BACKGROUND: Patient engagement and patient-centered care are critical in optimally managing patients with end-stage renal disease (ESRD). Understanding patient preferences is a key element of patient-centered care and shared decision making. The objective of this study was to elicit patients’ prefer...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauber, Brett, Caloyeras, John, Posner, Joshua, Brommage, Deborah, Belozeroff, Vasily, Cooper, Kerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532768/
https://www.ncbi.nlm.nih.gov/pubmed/28750605
http://dx.doi.org/10.1186/s12882-017-0665-8
_version_ 1783253519604645888
author Hauber, Brett
Caloyeras, John
Posner, Joshua
Brommage, Deborah
Belozeroff, Vasily
Cooper, Kerry
author_facet Hauber, Brett
Caloyeras, John
Posner, Joshua
Brommage, Deborah
Belozeroff, Vasily
Cooper, Kerry
author_sort Hauber, Brett
collection PubMed
description BACKGROUND: Patient engagement and patient-centered care are critical in optimally managing patients with end-stage renal disease (ESRD). Understanding patient preferences is a key element of patient-centered care and shared decision making. The objective of this study was to elicit patients’ preferences for the treatment of secondary hyperparathyroidism (SHPT) associated with ESRD using a discrete-choice experiment survey. METHODS: Clinical literature, nephrologist input, patient-education resources, and a patient focus group informed development of the survey instrument, which was qualitatively pretested before its administration to a broader sample of patients. The National Kidney Foundation invited individuals in the United States with ESRD who were undergoing hemodialysis to participate in the survey. Respondents chose among three hypothetical SHPT treatment alternatives (two medical alternatives and surgery) in each of a series of questions, which were defined by attributes of efficacy (effect on laboratory values and symptoms), safety, tolerability, mode of administration, and cost. The survey instrument included a best-worst scaling exercise to quantify the relative bother of the individual attributes of surgery. Random-parameters logit models were used to evaluate the conditional relative importance of the attributes. RESULTS: A total of 200 patients with ESRD completed the survey. The treatment attributes that were most important to the respondents were whether a treatment was a medication or surgery and out-of-pocket cost. Patients had statistically significant preferences for efficacy attributes related to symptom management and laboratory values, but placed less importance on the attributes related to mode of administration and side effects. The most bothersome attribute of surgery was the risk of surgical mortality. CONCLUSIONS: Patients with ESRD and SHPT who are undergoing hemodialysis understand SHPT and have clear and measurable treatment preferences. These results may help inform clinicians about patients’ preferences regarding treatment options for a common complication of ESRD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0665-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5532768
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55327682017-08-02 Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism Hauber, Brett Caloyeras, John Posner, Joshua Brommage, Deborah Belozeroff, Vasily Cooper, Kerry BMC Nephrol Research Article BACKGROUND: Patient engagement and patient-centered care are critical in optimally managing patients with end-stage renal disease (ESRD). Understanding patient preferences is a key element of patient-centered care and shared decision making. The objective of this study was to elicit patients’ preferences for the treatment of secondary hyperparathyroidism (SHPT) associated with ESRD using a discrete-choice experiment survey. METHODS: Clinical literature, nephrologist input, patient-education resources, and a patient focus group informed development of the survey instrument, which was qualitatively pretested before its administration to a broader sample of patients. The National Kidney Foundation invited individuals in the United States with ESRD who were undergoing hemodialysis to participate in the survey. Respondents chose among three hypothetical SHPT treatment alternatives (two medical alternatives and surgery) in each of a series of questions, which were defined by attributes of efficacy (effect on laboratory values and symptoms), safety, tolerability, mode of administration, and cost. The survey instrument included a best-worst scaling exercise to quantify the relative bother of the individual attributes of surgery. Random-parameters logit models were used to evaluate the conditional relative importance of the attributes. RESULTS: A total of 200 patients with ESRD completed the survey. The treatment attributes that were most important to the respondents were whether a treatment was a medication or surgery and out-of-pocket cost. Patients had statistically significant preferences for efficacy attributes related to symptom management and laboratory values, but placed less importance on the attributes related to mode of administration and side effects. The most bothersome attribute of surgery was the risk of surgical mortality. CONCLUSIONS: Patients with ESRD and SHPT who are undergoing hemodialysis understand SHPT and have clear and measurable treatment preferences. These results may help inform clinicians about patients’ preferences regarding treatment options for a common complication of ESRD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0665-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-07-28 /pmc/articles/PMC5532768/ /pubmed/28750605 http://dx.doi.org/10.1186/s12882-017-0665-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Hauber, Brett
Caloyeras, John
Posner, Joshua
Brommage, Deborah
Belozeroff, Vasily
Cooper, Kerry
Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
title Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
title_full Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
title_fullStr Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
title_full_unstemmed Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
title_short Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
title_sort hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532768/
https://www.ncbi.nlm.nih.gov/pubmed/28750605
http://dx.doi.org/10.1186/s12882-017-0665-8
work_keys_str_mv AT hauberbrett hemodialysispatientspreferencesforthemanagementofsecondaryhyperparathyroidism
AT caloyerasjohn hemodialysispatientspreferencesforthemanagementofsecondaryhyperparathyroidism
AT posnerjoshua hemodialysispatientspreferencesforthemanagementofsecondaryhyperparathyroidism
AT brommagedeborah hemodialysispatientspreferencesforthemanagementofsecondaryhyperparathyroidism
AT belozeroffvasily hemodialysispatientspreferencesforthemanagementofsecondaryhyperparathyroidism
AT cooperkerry hemodialysispatientspreferencesforthemanagementofsecondaryhyperparathyroidism